Related Experiment Videos
Infantile type 2 sialidosis in a Pakistani family--a clinical and biochemical study
Insights
This study identifies primary neuraminidase deficiency in siblings with rare genetic disorders. The findings highlight key clinical and biochemical markers for diagnosing this neurodegenerative condition.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- GM1-gangliosidosis is a lysosomal storage disorder.
- Primary neuraminidase deficiency is a rare genetic condition.
- Consanguineous parents increase the risk of rare genetic disorders.
Observation:
- Siblings presented with failure to thrive, coarsened facies, visceromegaly, and corneal opacities.
- Progressive neurological deterioration, cherry-red spots, and cataracts were observed.
- Abnormal oligosaccharide excretion and reduced neuraminidase activity were detected.
Findings:
- Patients exhibited primary neuraminidase deficiency.
- Reduced leukocyte and fibroblast neuraminidase activity confirmed the diagnosis.
- The mother was identified as a carrier, showing heterozygote levels.
Implications:
- This research clarifies the clinical and biochemical profile of primary neuraminidase deficiency.
- Early diagnosis and understanding of this condition are crucial for patient management.
- Further research into neuraminidase-related disorders is warranted.
Abstract:
Two siblings of consanguineous parents presented in infancy with failure to thrive, mild coarsening of facies, visceromegaly and corneal opacities. One showed reduced hepatic beta-galactosidase activity suggesting a GM1-gangliosidosis variant. Both patients developed progressive coarsening of facies, slow neurological deterioration, macular cherry-red spots and punctate cataracts over the first decade. Urine screening with thin layer chromatography revealed abnormal excretion of two slow-moving oligosaccharide bands and leukocyte and fibroblast neuraminidase activity was grossly reduced. The mother, phenotypically normal, showed levels of neuraminidase compatible with heterozygosity. These patients have primary neuraminidase deficiency. The clinical and biochemical variables are reviewed.